Dendreon Rises After Winning Approval for Cancer Drug (Update2)
April 29 (Bloomberg) — Dendreon Corp. won approval for its first product, a vaccine to fight prostate cancer, after a three-year battle with U.S. regulators. Shares surged the most in a year in New York trading.
Read more on Bloomberg
America’s First Therapeutic Cancer Vaccine
Last Thursday the Food and Drug Administration approved Provenge for the treatment of advanced prostate cancer. Provenge is the first therapeutic vaccine to be approved in the U.S. for cancer treatment, ushering in what may be a new era in immune-based cancer treatments. Approval marks the successful conclusion of a 20-year odyssey with some remarkable twists and turns. My part of the story …
Read more on The Atlantic
The best “treatment” for cancer is to prevent it from occurring. Research is ongoing to evaluate environmental and lifestyle factors that may be associated with an increased incidence of cancer. Identifying such risk factors may allow individuals to modify lifestyle choices in order to reduce their risk of developing cancer.
The Million Women Study in the United Kingdom involved over 1.3 million middle-aged women who responded to a questionnaire regarding sociodemographic and personal information, including alcohol consumption. These women were followed for several years in an effort to determine how reproductive and lifestyle factors affect women’s health.
» Read more: Terramed Alliance News Moderate Alcohol Consumption Increases Risk of Cancer in Women